This trial is designed to study the safety and effectiveness of different cancer treatments in people with NSCLC that can't be removed by surgery and have certain oncogenic mutations or high TMB.
7 Primary · 55 Secondary · Reporting Duration: Baseline, every 4 weeks until disease progression, up to approximately 6 years
Active Control
Experimental Treatment
1000 Total Participants · 10 Treatment Groups
Primary Treatment: Atezolizumab · No Placebo Group · Phase 2 & 3
Age 18+ · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: